Sentinel lymph node micrometastasis and risks of breast cancer recurrence: a systematic review and meta analysis

doi:10.3877/cma.j.issn.1674-0793.2019.01.018

Abstract

Abstract:

Objective

To systemically evaluate the recurrence related event rate (RRER) of breast cancer with sentinel lymph node micrometastasis (SLN MIC) without axillary lymph node dissection (ALND).

Methods

Databases such as PubMed, EMBASE, WanFang Data, CNKI and CBM were searched comprehensively for studies about SLN for breast cancer from foundation to May 1st, 2018. On the basis of the inclusion and exclusion criteria, extracting data, assessing methodological quality and analyzing results was achieved. RevMan 5.2 was used to carry out statistical analyses.

Results

A total of six studies, including 3 prospective observational studies and 3 retrospective studies involving 1 730 patients of whom 370 had SLN MIC and 1 360 had negative SLN (-), were qualified for final analysis. The odds ratio (OR) of RRER between group SLN MIC and group SLN (-) of breast cancer patients who didn’t performed ALND was 1.37 (95%CI: 0.72-2.59, I²=47%, P=0.34), without statistical differences. In addition, there was also no statistical difference in regional recurrence rate between group SLN MIC and group SLN(-) of breast cancer patients without ALND (OR=1.49, 95%CI: 0.75~2.97, I²=40%, P=0.26).

Conclusion

Compared with patients with negative SLN, SLN MIC does not increase the risk of recurrence in breast cancer patients without ALND.

Key words: Breast neoplasms, Meta-analysis, Sentinel lymph node biopsy, Recurrence, Sentinel lymph node micrometastasis

Denghui Wei, Zhihong Xu, Lili Xie, Hui Han, Shunguo Lin, Chunsen Xu. Sentinel lymph node micrometastasis and risks of breast cancer recurrence: a systematic review and meta analysis[J]. Chinese Archives of General Surgery(Electronic Edition), 2019, 13(01): 80-84.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2019.01.018

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2019/V13/I01/80

Figures/Tables 7

References 16

[1]	Wells GA, Shea B, O'connell D. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses[EB/OL]. 2012. URL
[2]	Langer I, Guller U, Viehl CT, et al. Axillary lymph node dissection for sentinel lymph node micrometastases may be safely omitted in early-stage breast cancer patients: long-term outcomes of a prospective study[J]. Indian J Surg Oncol, 2010, 1(1): 59-67.
[3]	Pepels MJ, de Boer M, Bult P, et al. Regional recurrence in breast cancer patients with sentinel node micrometastases and isolated tumor cells[J]. Ann Surg, 2012, 255(1): 116-121.
[4]	Guenther J, Hansen NM, Difronzo LA, et al. Axillary dissection is not required for all patients with breast cancer and positive sentinel nodes[J]. Arch Surg, 2003, 138(1): 52-56.
[5]	Gloyeske NC, Goreal W, O'neil M, et al. Outcomes of breast cancer patients with micrometastases and isolated tumor cells in sentinel lymph nodes[J]. In Vivo, 2011, 25(6): 997-1001.
[6]	Tvedskov T, Jensen M-B, Ejlertsen B, et al. Prognostic significance of axillary dissection in breast cancer patients with micrometastases or isolated tumor cells in sentinel nodes: a nationwide study[J]. Breast Cancer Res Treat, 2015, 153(3): 599-606.
[7]	Cyr A, Gillanders WE, Aft RL, et al. Micrometastatic disease and isolated tumor cells as a predictor for additional breast cancer axillary metastatic burden[J]. Ann Surg Oncol, 2010, 17(3): 303-311.
[8]	Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM[J]. Ann Surg Oncol, 2010, 17(6): 1471-1474.
[9]	中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2017年版)[J]. 中国癌症杂志, 2017, 27(9): 695-759.
[10]	Hansen NM, Grube B, Ye X, et al. Impact of micrometastases in the sentinel node of patients with invasive breast cancer[J]. J Clin Oncol, 2009, 27(28): 4679-4684.
[11]	Imoto S, Ochiai A, Okumura C, et al. Impact of isolated tumor cells in sentinel lymph nodes detected by immunohistochemical staining[J]. Eur J Surg Oncol, 2006, 32(10): 1175-1179.
[12]	Pugliese MS, Beatty JD, Tickman RJ, et al. Impact and outcomes of routine microstaging of sentinel lymph nodes in breast cancer: significance of the pN0(i+) and pN1mi categories[J]. Ann Surg Oncol, 2009, 16(1): 113-120.
[13]	Cox C, Kiluk J, Riker A, et al. Significance of sentinel lymph node micrometastases in human breast cancer[J]. J Am Coll Surg, 2008, 206(2): 261-268.
[14]	de Boer M, van Deurzen CH, van Dijck JA, et al. Micrometastases or isolated tumor cells and the outcome of breast cancer[J]. N Engl J Med, 2009, 361(7): 653-663.
[15]	Huang TW, Kuo KN, Chen KH, et al. Recommendation for axillary lymph node dissection in women with early breast cancer and sentinel node metastasis: A systematic review and meta-analysis of randomized controlled trials using the GRADE system[J]. Int J Surg, 2016, 34: 73-80.
[16]	Galimberti V, Cole BF, Zurrida S, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial[J]. Lancet Oncol, 2013, 14(4): 297-305.

纳入研究	研究类型	SLN阴性组(例)	SLN MIC组(例)	结局指标	随访时间（月）
Langer等2010^[2]	观察性研究	123	27	1、2、3	77
Pepels等2012^[3]	观察性研究	1 077	141	1、2	60
Guenther等2003^[4]	观察性研究	23	16	1、3	32
Gloyeske等2011^[5]	回顾性研究	9	13	1、2、3	52
Tvedskov等2015^[6]	回顾性研究	104	136	1、2、3	72
Cyr等2010^[7]	回顾性研究	24	37	1、2、3	55

纳入研究	研究类型	SLN阴性组(例)	SLN MIC组(例)	结局指标	随访时间（月）
Langer等2010^[2]	观察性研究	123	27	1、2、3	77
Pepels等2012^[3]	观察性研究	1 077	141	1、2	60
Guenther等2003^[4]	观察性研究	23	16	1、3	32
Gloyeske等2011^[5]	回顾性研究	9	13	1、2、3	52
Tvedskov等2015^[6]	回顾性研究	104	136	1、2、3	72
Cyr等2010^[7]	回顾性研究	24	37	1、2、3	55

第一作者发表年	暴露组代表性	非暴露组代表性	暴露因素确定方法	有无明确的结局指标	组间可比性	结局指标评价	随访时间	随访完整性	总分（分）
Langer等2010^[2]	1	1	1	1	2	1	1	1	9
Pepels等2012^[3]	1	1	1	1	2	1	1	1	9
Guenther等2003^[4]	1	1	0	1	2	1	1	1	8
Gloyeske等2011^[5]	1	1	1	1	1	1	1	1	8
Tvedskov等2015^[6]	1	1	1	1	1	0	1	1	7
Cyr等2010^[7]	1	1	1	1	1	0	1	1	7

第一作者发表年	暴露组代表性	非暴露组代表性	暴露因素确定方法	有无明确的结局指标	组间可比性	结局指标评价	随访时间	随访完整性	总分（分）
Langer等2010^[2]	1	1	1	1	2	1	1	1	9
Pepels等2012^[3]	1	1	1	1	2	1	1	1	9
Guenther等2003^[4]	1	1	0	1	2	1	1	1	8
Gloyeske等2011^[5]	1	1	1	1	1	1	1	1	8
Tvedskov等2015^[6]	1	1	1	1	1	0	1	1	7
Cyr等2010^[7]	1	1	1	1	1	0	1	1	7

Please choose a citation manager

Content to export